You are here

Positive Results From Pivotal Study of New IOL for Cataract Surgery

Lens improved intermediate and near visual acuity compared to a standard monofocal lens

A pivotal clinical trial of the Tecnis Symfony one-piece acrylic intraocular lens (IOL) met its primary endpoint of improved intermediate vision, Abbott has announced.

Data from this study showed that people who received the Symfony lens achieved significantly improved intermediate, as well as near, vision compared to those who received a monofocal IOL. The data were presented Sunday at the American Society of Cataract and Refractive Surgery (ASCRS)–American Society of Ophthalmic Administrators meeting in New Orleans by Jason Jones, MD, of the Jones Eye Clinic in Sioux City, Iowa.

"Many people with cataracts are asking for an option that will help them perform near activities like reading, use their computers and tablets at intermediate distance, as well as see objects that are far away," said Dr. Jones, an investigator on the study. "The data from this study showed that patients who received the Symfony lens were more likely to achieve improved intermediate and near vision, while maintaining similar distance vision compared with patients who received a standard IOL."

In a cataract, the lens inside the eye becomes cloudy. Many patients notice the symptoms of a cataract as cloudy or blurred vision, faded color patterns, poor night vision, doubling of images, or frequent need to change their glasses prescription.

Cataract surgery is one of the most common surgeries performed by eye surgeons, with almost four million surgeries performed in the U.S. every year. That number is expected to grow significantly as the population ages and as new lens choices are introduced that provide people more options for improving their vision and maintaining their active lifestyle after cataract surgery. Though it is common in older adults, demographics are changing among cataract patients. In 2016 it was estimated that 900,000 cataract procedures would be performed on people in the United States younger than 65 years old.

Unlike monofocal IOLs that provide a fixed-focus point at one particular distance, the Symfony IOL has proprietary optical features designed to elongate the range of focus of the eye and provide a continuous range of vision at near, intermediate, and distance. The Symfony IOL has been widely studied, with data from more than seven studies in more than 2,000 eyes being collected. The lens is approved in more than 50 countries around the world. In the U.S., it is an investigational lens and is not available for commercial use.

Source: Abbott; May 8, 2016.

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
National Statistics Report Factors In Race, Ethnicity for the First Time